文献速递肾小球疾病

糖皮质激素治疗肾小球肾炎:是时候重新思考了

Steroids as treatment for glomerulonephritis: time for a rethink.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

糖皮质激素近70年来一直是炎性和自身免疫性肾病治疗的基石,但临床仍不清楚如何「最佳」使用。持续使用糖皮质激素伴随显著不良事件,导致患者过早死亡。避免或最小化糖皮质激素是可行的,并已在多种肾小球疾病中通过新型药物或创新方案得到验证。

要点

  • 糖皮质激素长期治疗有显著不良事件,增加过早死亡风险。
  • 避免或最小化糖皮质激素在多种肾小球疾病中可行且已被验证。
  • 应重新审视糖皮质激素使用策略并教育医师优化炎性肾病管理。

核心结论

  • 糖皮质激素治疗肾小球肾炎的最佳用法仍不明确,需重新思考其使用策略。
  • 避免或最小化糖皮质激素是可行方向,已有新型药物或创新方案支持。

主要发现

  • 糖皮质激素持续使用与显著不良事件相关,并导致患者过早死亡。

临床怎么用

  • 临床应认真审视糖皮质激素的使用,并教育医师更好地管理炎性肾脏疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucocorticoids have been a cornerstone of treatment for inflammatory and autoimmune kidney diseases for almost 70 years, yet it is fair to say, we still do not know how 'best' to use them. Significant adverse events are associated with their continued use, which contribute to premature patient mortality. Steroid avoidance or minimization is possible and has been tested in various glomerular diseases, as a result of novel agents or innovative regimens using established therapeutics. It is now time to seriously address our use of steroids and educate physicians on better ways of managing inflammatory kidney diseases.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Hendra H, Salama AD. Steroids as treatment for glomerulonephritis: time for a rethink. Nephrol Dial Transplant. 2022. PMID: 33188694. doi:10.1093/ndt/gfaa267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。